close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

VA/DOD

Military personnel may receive coverage for SYNVISC® through the Veterans Administration or through the Department of Defense (TRICARE). Protocol for access to SYNVISC varies according to each plan.

A general overview of coverage is provided below:

Veterans Administration (VA)
U.S. veterans receiving medical benefits through the VA may access SYNVISC through their local VA facility, managed by regional Veterans Integrated Service Networks (VISNs). Although it is not listed on the national VA formulary for drugs and biologics, SYNVISC may be considered for coverage through a local VISN as a non-formulary drug.

Department of Defense (TRICARE)
Active military personnel and their families who receive medical and prescription benefits through one of the DOD TRICARE plans may be covered for SYNVISC as a physician-administered drug. To learn more, patients can visit http://www.tricare.mil.

Questions about VA/DOD coverage?
Call SYNVISC ConnectionSM at 1-800-982-8292, M-F, 9 am -6 pm (EST).

Providers retain responsibility for determining reimbursement and insurance issues related to their patients. Genzyme cannot be responsible for failure of a provider to obtain reimbursement.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)